New ulcer drug formulations tested in healthy adults
NCT ID NCT06902818
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage study tested two different tablet versions of a drug for gastric ulcers in 46 healthy adults. Participants received a single dose of each formulation on separate occasions to compare how the drug moves through the body and to check for side effects. The goal is to see which version works better and is safer before testing in patients with ulcers.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AD-115A and AD-1151 (oral tablets for gastric ulcer)
What this could lead to
If successful, this study could help determine which formulation is better absorbed and safer, potentially leading to an improved treatment option for gastric ulcers.
What could go wrong
This is a very early Phase 1 trial in only 46 healthy people, not patients with ulcers. It only measures drug levels and short-term safety, not whether the drug actually heals ulcers.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC ULCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
H PLUS YANGJI HOSPITAL, Seoul,
Seoul, South Korea